

3/8

Enc Date: 07/05/2021

Boyd, Nikolas

DOB: 6/2/1956 Age: 65 yrs Male

SURGICAL PATHOLOGY (ExtID# NVP-21-00771) (Order 1381003483)

Status; Preliminary result (Collected: 7/6/2021 00:00)

Results

Patient Demographics

Patient Name Boyd, Nikolas Sex Male DOB

6/2/1956

Address (Temporary)

Contact Numbers

Order: 1381003483

Result Information

Collected Date and Time 7/6/2021 12:00 AM

Lab Received Date and Time 7/6/2021 12:00 AM

Filed in EpicCare Date and Time

7/11/2021 1:50 PM

Pathology Laboratory

Pathology Laboratory

CPMC PACIFIC CAMPUS PATHOLOGY LABORATORY

2333 Buchanan St

San Francisco CA 94115

Tel: 415-600-2200

Lab Director: Richard Garcia Kennedy, M.D.

SURGICAL PATHOLOGY

Status: Preliminary result

Narrative

Performed by: CPMC PACIFIC CAMPUS PATHOLOGY LABORATORY

CASE: NVP-21-00771 PATIENT: NIKOLAS BOYD

TISSUES:

A. 3cm Mesenteric Node; B. 3cm Mesenteric Node - FNA Slides Referred; C. Flow Cytometry CLINICAL HISTORY:

Fluid Received: a) Core biopsy processed 07/06 b) FNA - 25ml opaque formalin for CB c) RPMI for Flow Fixed Slides Received: b) 2 CellBlkMade/InterpForDiagnosis

+ 3 cm mesenteric node looks like lymphoma.

PRELIMINARY FINDINGS:

PRELIMINARY UPDATE by Dr. M. Patino (contact pager 415-232-5214), on 7/10/2021, pending FISH, repeat CD10 and cMyc IHC. Diagnosis of large B-cell lymphoma has been stablished, but FISH will define diffuse large

Enc Date: 07/05/2021

B vs high grade B-cell lymphoma

Lymph node, mesenteric, CT guided core biopsy, fine needle aspiration and flow cytometric analysis:

- Large B-cell lymphoma (CD20 positive).
- Flow cytometry

Cytologic and histologic evaluation:

A. Core biopsy: Sections show an abnormal proliferation. Immunostains and in situ hybridization have been examined to characterize the proliferation:

CD20 and Pax5 positive

CD5 and CD3 negative

CD30 rare positive cells, less than 1%

Mum-1 positive (>30% large cells)

BCL2 positive (>30% large cells)

BCL6 positive (>30% large cells)

Ki67 at least 70-80% in large cells

CD21 shows rare follicle in the background, but most of the process appears diffuse.

In situ hybridization for EBER (EBV in situ) negative

The proliferation is negative for non-hematolymphoid markers: Keratin CAM5.2, AE1/AE3, CD117 (c-kit), and Sox10.

B. Cytologic review of smears provided and H and E sections obtained from cell block of the FNA material shows an atypical lymphoid infiltrate (part B).

GROSS DESCRIPTION:

- A. The specimen is received in a container with formalin, labeled with the patient's name, date of birth, and "MRN." It consists of multiple white-pink cylindrical cores ranging from 0.3-1.5 cm in length and measuring 0.1 cm in diameter. The specimen is wrapped and submitted entirely in two cassettes labeled Al and A2.
- B. Received material in formalin from which cell block B1 and corresponding H and E sections are obtained. Two alcohol fixed smears received and stained by the Papanicolaou stained method (B1-B2)
- C. Additionally received in an RPMI tube labeled with the patient's name, date of birth, and "MRN." Tissue is identified in the RPMI tube. The specimen is sent out for additional studies. No histologic sections are submitted.

IMJ JLF 7/6/2021 10:18 PM

Enc Date: 07/05/2021

The immunohistochemical stain (s) and in situ hybridization probe stain (s) reported above were developed and their performance characteristics determined by California Pacific Medical Center Department of Pathology. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Each immunoperoxidase stain listed in this report is a single antibody stain procedure, except for the P63/p504s stain, which is a multiplex stain procedure. Each in situ hybridization stain is a single probe stain procedure, except for the Her-2/neu dual ISH stain, which is a multiplex probe stain procedure.

Flow Cytometry Analysis Technical component performed at Neo Genomics Professional interpretation at CPMC by Dr. M. Patino

Patient Name: Boyd, Nikolas Patient DOB / Sex: 06/02/1956 / M

Specimen Type: Tissue

Body Site: 3CM MESENTERIC NODE Specimen ID: NVP-21-00771

Ordering Physician(s): Maria M Patino, MD Treating Physician(s): Ralph M. Koenker, M.D Accession / CaseNo: 4048626 / FLT21-056285

Collection Date: 07/06/2021

Received Date: 07/08/2021 03:41:00 AM PDT

Reason for Referral: LEFT UPPER QUADRANT ABDOMINAL SWELLING, MASS AND

LUMP,

SECONDARY MALIGNANT NEOPLASM OF UNSPECIFIED SITE

Interpretation: Consistent with CD10-positive B-cell lymphoproliferative disorder.

Comments: Flow cytometry shows monoclonal B-cells (19% of total cells) with \dim CD10 expression without CD5 , consistent with a CD10-positive B-cell lymphoproliferative disorder. The main differential diagnosis includes follicular lymphoma, Burkitt lymphoma and large B-cell lymphoma.

Flow Differential (%) and Population Analysis:

Lymphocytes: 93.0%

T-cells (75% of lymphoid cells) show a CD4/CD8 ratio about 5.0 without overt phenotypic abnormality.

Enc Date: 07/05/2021

NK-cells (1% of lymphoid cells) are unremarkable. Mature B-cells (19% of lymphoid cells) are small in

size based on the forward scatter pattern and show: CD5 neg, CD10+, CD11c+dim, CD19+, CD20+bright,

CD23+, CD38+ with surface kappa/lambda light chain restriction (kappa:lambda 3.2).

Monocytes: 0.5%

Monocytes show phenotypic evidence of maturation without dysmaturation.

Granulocytes: 5.4%

Granulocytes show phenotypic evidence of maturation without dysmaturation.

CD45 Dim: 0.5%

CD34+ cells (0.1% of total cells) are not increased. Precursor B-cells (% of total cells) are unremarkable.

CD45 Neg: 0.6%

Erythroids and cell debris, unremarkable.

Plasma Cells: 0.0%

Plasma cells are not increased and show unremarkable surface marker expression.

CD34+: 0.1%

Specimen Viability: 78.8% Cell Yield: 0.42 Million

Markers Performed:

CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD34, CD38, CD45, CD56, Kappa, Lambda (17 Markers)

CPT Codes: 88185x17

The Technical Component Processing and Analysis of this test was completed at NeoGenomics California, 31 Columbia, Aliso Viejo, CA / 92656 / 866-776-5907 / CLIA #05D1021650 / Medical Director(s): Sally Agersborg, M.D. The Professional Component of this test was completed at Novato Community Hospital, 180 Rowland Way, Novato, CA 94945 / Phone: (415) 209-1424 / Fax: (415) 209-1421.

This test was developed and its performance characteristics determined by the performing laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.

Images that may be included within this report are representative of the patient but not all testing in its entirety and should not be used to render a result.

The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

7/8

Boyd, Nikolas

DOB: 6/2/1956 Age: 65 yrs Male

Enc Date: 07/05/2021

Maria M. Patino M.D. Report read and electronically signed: 7/7/2021 6:44:46PM

Maria M. Patino M.D. Report read and electronically signed: 7/11/2021 1:49:16PM

All pathology specimens processed at Sutter California Pacific Medical Center, Davies Campus, Castro St. & Duboce Ave., San Francisco, CA 94114, CLIA # 05-D0643656.

Diagnoses rendered at Sutter California Pacific Medical Center, Davies Campus, Castro St. & Duboce Ave., San Francisco, CA 94114, CLIA # 05-D0643656.

Any intra-procedural consultations performed at Sutter Novato Community Hospital, 180 Roland Way, Novato, CA 94945, CLIA #05D0663151.

Specimen Collected: 07/06/21 00:00

Last Resulted: 07/11/21 13:50

② Order Details → View Encounter U Lab and Collection Details → Routing → Result History - Result Edited

Testing Performed By

Lab
CPMC PACIFIC CAMPUS PATHOLOGY LABORATORY
2333 Buchanan St
San Francisco CA 94115
Tel: 415-600-2200
Lab Director: Richard Garcia Kennedy, M.D.

Patient Release Status:

This result is not viewable by the patient.

MHO Release Date & Time

Authorizing Provider

Ordering Provider

Koenker, Ralph M, MD

Koenker, Ralph M, MD

Result History

SURGICAL PATHOLOGY (Order #1381003483) on 7/11/2021 - Order Result History Report

Order Providers

Authorizing Provider

Encounter Provider

(ID # 30069432) Koenker, Ralph M, MD

None

Detailed Information

Priority and Order Details

Collection Information

Original Encounter

View Parent Encounter

NCH Case Mgmt (415) 209-1471

8/8

Enc Date: 07/05/2021

Results Encounter

View Encounter